Beacon Capital Management »

Galectin Therapeutics shares owned by Beacon Capital Management

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by Beacon Capital Management from 13F filings

Historical chart of Beacon Capital Management investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by Beacon Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by Beacon Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $46k 24k 1.92
2023-09-30 $18k 13k 1.44
2023-06-30 $18k 13k 1.44
2023-03-31 $27k 13k 2.10
2022-12-31 $14k 13k 1.13

More positions owned by Beacon Capital Management

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Vanguard Index Fds Total Stk Mkt (VTI)
Spdr Dow Jones Indl Average Ut Ser 1 (DIA)
Vanguard Admiral Fds 500 Val Idx Fd (VOOV)
Vanguard Index Fds Large Cap Etf (VV)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Vanguard World Mega Grwth Ind (MGK)
Vanguard Index Fds Growth Etf (VUG)
Apple (AAPL)
Vanguard World Fds Inf Tech Etf (VGT)
Amazon (AMZN)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr S&p 500 Grwt Etf (IVW)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)

View all positions for Beacon Capital Management

Top funds holding Galectin Therapeutics

Vanguard Group
Advisor Group Holdings
Geneos Wealth Management
Atria Wealth Solutions
Sontag Advisory
Cambridge Investment Research Advisors
Commonwealth Equity Services
Cutter & CO Brokerage
683 Capital Management
Horizon Kinetics Asset Management
D.A. Davidson & Co.
Stratos Wealth Partners
William Blair $ Company
Independent Advisor Alliance
Solutions 4 Wealth

View all funds holding Galectin Therapeutics